An Open-label, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Oral CTAP101 (Calcifediol) Extended-release Capsules in Japanese and Non-Japanese Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Calcifediol (Primary)
- Indications Secondary hyperparathyroidism; Vitamin D deficiency
- Focus Adverse reactions; Pharmacokinetics
- Sponsors OPKO Health; OPKO Renal
- 27 Sep 2019 Status changed from active, no longer recruiting to completed.
- 23 Jul 2019 Planned End Date changed from 26 Jun 2019 to 26 Aug 2019.
- 28 May 2019 Planned End Date changed from 26 Apr 2019 to 26 Jun 2019.